Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

Lignende værker

• Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
  af: Borte, Michael, et al.
  Udgivet: (2011)
• Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
  af: Jolles, Stephen, et al.
  Udgivet: (2018)
• Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
  af: Jolles, Stephen
  Udgivet: (2013)
• Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
  af: Kanegane, Hirokazu, et al.
  Udgivet: (2014)
• Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age
  af: Patel, Niraj C., et al.
  Udgivet: (2015)